SCHEMBL280048

SCHEMBL280048

Cc1ccc(C(=O)COCc2ccnn2C)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.43
ALDH1A1 P00352 4/20 0.43
CASP3 P42574 2/20 0.43
SENP8 Q96LD8 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
SENP6 Q9GZR1 2/20 0.43
HPGD P15428 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
KMT2A Q03164 3/20 0.37
DAO P14920 1/20 0.37
MAPK1 P28482 1/20 0.36
NAMPT P43490 1/20 0.36
HTR1A P08908 1/20 0.35
MEN1 O00255 1/20 0.34
ESR1 P03372 1/20 0.34
ALOX12 P18054 1/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279929 0.76 POLB (0.47) POLBALDH1A1CASP3SENP8SENP7
SCHEMBL26854359 0.67 KMT2A (0.40) L3MBTL1KMT2A
SCHEMBL23283979 0.67 KMT2A (0.47) ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL31506264 0.67 KMT2A (0.41) ALDH1A1L3MBTL1KMT2AMAPK1MEN1
SCHEMBL24158724 0.65 KMT2A (0.46) L3MBTL1KMT2A
SCHEMBL6394534 0.65 GSK3B (0.62) POLBALDH1A1CASP3SENP8SENP7
SCHEMBL27907453 0.65 ALDH1A1 (0.60) POLBALDH1A1CASP3SENP8SENP7
SCHEMBL15979700 0.65 DAO (0.61) POLBALDH1A1CASP3SENP8SENP7
SCHEMBL7036021 0.64 KMT2A (0.39) L3MBTL1KMT2A
SCHEMBL21576138 0.64 KMT2A (0.45) ALDH1A1HPGDL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL POLB 4352/4885ALDH1A1 2047/4885CASP3 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.